Enoxaparin Sodium Injection IP

Product

KAIVEXIN® – 20/40/60/80

Route of administration

Subcutaneous / Intravascular

Composition – Each Pre-filled Syringe Contains:

  • Enoxaparin Sodium I.P..….20 mg

  • (Porcine Derived)

  • Equivalent to 2000 IU of Anti-factor Xa Activity

  • Water For Injections I.P………..q.s. to 0.2 mL

Composition – Each Pre-filled Syringe Contains:

  • Enoxaparin Sodium I.P..….40 mg

  • (Porcine Derived)

  • Equivalent to 4000 IU of Anti-factor Xa Activity

  • Water For Injections I.P………..q.s. to 0.4 mL

Composition – Each Pre-filled Syringe Contains:

  • Enoxaparin Sodium I.P..….60 mg

  • (Porcine Derived)

  • Equivalent to 6000 IU of Anti-factor Xa Activity

  • Water For Injections I.P………..q.s. to 0.6 mL

Composition – Each Pre-filled Syringe Contains:

  • Enoxaparin Sodium I.P..….80 mg

  • (Porcine Derived)

  • Equivalent to 8000 IU Anti-factor Xa Activity

  • Water For Injections I.P……….q.s. to 0.8 mL

Indications

  • The prophylaxis of thromboembolic disorders of venous origin, in particular those which may be associated with orthopaedic or general surgery.

    • The prophylaxis of venous thromboembolism in medical patients bedridden due to acute illnesses including cardiac insufficiency, respiratory failure, or severe infections.

    • The treatment of venous thromboembolic disease presenting with deep vein thrombosis, pulmonary embolism or both.

    • The treatment of unstable angina and non-Q-wave myocardial infarction administered concurrently with aspirin.

    • Treatment of acute ST-segment Elevation Myocardial Infarction (STEMI) including patients to be managed medically or with subsequent

  • Percutaneous Coronary Intervention (PCI). The prevention of thrombus formation in the extracorporeal circulation during haemodialysis